Cancer Research Programs
Cedars-Sinai Cancer has fostered the development of four research programs derived from our institutional strengths and priorities. As an emerging institute, we have concentrated efforts and resources to make the programs successful, well-funded, and interactive with each other, rather than attempting to nurture multiple possible programs.
Cedars-Sinai Cancer supports four programs, oriented toward cancer biology, experimental therapeutics, cancer prevention and control studies, and liver metastasis.
The purpose of the Cancer Biology Program (CBP) is to advance the understanding of cancer pathogenesis and facilitate the translation of basic science discoveries to the clinic. Under the leadership of Dolores Di Vizio, MD, PhD, and Xue (Sean) Li, PhD research identifies communication between cancer cells and associated non-cancer cells critical to initiation, progression, and metastasis. The CBP supports bench research and provides a means of bringing concepts in clinical trials back to the bench. There is an intimate reciprocal interaction with the Experimental Therapeutics Program and the Cancer Prevention and Genetics Programs (CPGP). As a community-based medical center, the patient-centered ethos of Cedars-Sinai is engrained in the CBP. The character of the Program is inherently a product of its constituency of clinician-researchers, chemists, biologists, and physicists that consistently look to improve patient outcomes.
The Cedars-Sinai Experimental Therapeutics Program is a new and progressive model for clinical-translational research, both locally and nationally, that will bring the unique clinical strengths of Cedars Cancer to problems addressed in translational research efforts. Under the leadership of Edwin Posadas, MD, and Stephen Shiao, MD, PhD, the Experimental Therapeutics Program is composed of physicians and scientists who have dedicated their careers to improving outcomes for cancer patients by combining the latest scientific discoveries with innovative and compassionate clinical care. The program partners with other areas of the Cancer Center to bring scientific discoveries to patients while helping our scientists to remain focused on the most urgent needs faced by cancer patients and their loved ones.
The Cancer Prevention and Control Program (CPCP), under the guidance and leadership of Marc Goodman, MD, MPH, and Patricia Thompson, PhD, investigates cancer etiology through genetic and epidemiological risk with the goal of using new knowledge to reduce incidence and mortality in diverse populations.
This program represents the only coordinated, multi-investigator effort in the nation to focus on the causes of and approaches to address liver metastasis from cancers of the prostate, pancreas and colon. The four integrated projects point to key roles for critical molecular signaling axes in mediating liver metastasis, through mechanisms likely common across many tumor types. The clinical capabilities across oncology and hepatology will enable translation of the mechanistic findings.
Have Questions or Need Help?
If you have any questions or wish to learn about Cedars-Sinai Cancer, please send us a message.
8700 Beverly Blvd.
North Tower Mezzanine, C2004
Los Angeles, CA 90048